Table 3.

Outcome after RIC/NMA HCT: multivariate analysis

Outcome	Variable	RR	95% CI	P Value
Overall Survival	Consolidation
	No	1
	Yes	0.886	0.71 – 1.10	0.28
	Donor Source:
	Matched Sibling	1
	Matched URD	0.88	0.68 – 1.14	0.34
	Partially matched URD	1.03	0.71 – 1.51	0.86
	UCB	1.60	1.18 – 2.16	0.002
	Cytogenetics
	Intermediate	1
	Unfavorable	1.74	1.36–2.22	<0.0001
	Other/Missing	1.20	0.92 – 1.56	0.18
	Age
	<45	1
	45–60	1.22	0.83 – 1.79	0.31
	>60	1.51	1.03 – 2.2	0.03
	Gender
	Male	1
	Female	0.78	0.63 – 0.97	0.02
TRM	Consolidation
	No	1
	Yes	0.74	0.53 – 1.04	0.08
	Donor Source
	Matched Sibling	1
	Matched URD	0.998	0.65 – 1.52	0.99
	Partially matched URD	1.371	0.79 – 2.39	0.26
	UCB	3.83	2.25 – 6.54	<0.0001
	Conditioning
	Flu/Bu	1
	Flu/Mel	1.6	1.05 – 2.43	0.03
	Flu/Other	0.65	0.38 – 1.14	0.13
	TBI-based	0.94	0.56 – 1.6	0.80
	Age
	<45	1
	45–60	1.2	0.63–2.28	0.58
	>60	1.96	1.04–3.67	0.04
	Gender
	Male	1
	Female	0.65	0.46–0.91	0.013
Relapse	Consolidation
	No	1
	Yes	1.03	0.77–1.36	0.86
	Cytogenetics
	Intermediate	1
	Unfavorable	1.87	1.38–2.5	<0.0001
	Other/Missing	1.17	0.83 – 1.66	0.37
	WBC
	< 5.0	1
	>= 5.0	0.77	0.59 – 0.99	0.05
DFS	Consolidation
	No	1
	Yes	0.87	0.7–1.07	0.19
	Cytogenetics
	Intermediate	1
	Unfavorable	1.65	1.29–2.1	<0.0001
	Other/Missing	1.19	0.92 – 1.55	0.19
	Gender
	Male	1
	Female	0.75	0.60–0.92	0.0071
	Donor Source
	Matched Sibling Donor	1
	Matched URD	0.84	0.64 – 1.09	0.20
	Partially matched URD	0.94	0.64 – 1.36	0.72
	UCB	1.37	1.01 – 1.85	0.04

Note: Relapse and DFS models were stratified on ATG/Alemtuzumab use